Research programme: cancer therapeutics - Inflection Biosciences

Drug Profile

Research programme: cancer therapeutics - Inflection Biosciences

Alternative Names: IBL-100 series; IBL-202; IBL-301

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator Spanish National Cancer Research Centre
  • Developer Inflection Biosciences; Multiple Myeloma Research Foundation; University of Sydney
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 14 Apr 2016 Pharmacokinetic and pharmacodynamic data from a preclinical study in cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 09 Feb 2015 Preclinical trials in Multiple myeloma in USA (PO)
  • 03 Dec 2014 Preclinical trials in Haematological malignancies in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top